A
ApnimedClinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.
3 Pulse stories
AH
Assort HealthAssort Health builds AI voice agents that automate patient access workflows for healthcare organizations, including scheduling, intake, referrals, and insurance verification.
2 Pulse stories
Total Raised
$222M
ApnimedAssort Health
Last Valuation
$1.2B
ApnimedAssort Health
Biotech
Sector
Biotech
2017
Founded
2023
Cambridge, Massachusetts
HQ
San Francisco, California
Public (APMD)
Status
Private
Apnimed investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
Assort Health investors
Menlo VenturesLightspeed Venture PartnersFelicisFirst Round CapitalChemistryLiquid 2 VenturesQuiet CapitalA* Capital
Data from Value Add Pulse coverage and company research — see the full threads for Apnimed and Assort Health.